12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Company News  |  Deals

Med BioGene, Precision Therapeutics, Signal Genetics deal

Med BioGene said it accepted an amended offer from Precision to license exclusive, worldwide rights to develop and commercialize its LungExpress Dx technology for $2.3 million up front and high-single digit...

Read the full 144 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >